苏州瑞博生命科学公司扩展了siRNA平台,以向脏,心脏和脂肪,在临床前试验中实现强大的基因沉默. Suzhou Ribo Life Science expanded its siRNA platform to target kidneys, heart, and fat, achieving strong gene silencing in preclinical tests.

苏州瑞博生命科学公司已扩展其siRNA传递平台RiboPepSTARTM,超越肝脏以向脏,心脏和脂肪组织,在各物种的细胞中显示高达80%的基因敲击,96%的灵长类脂肪组织. Suzhou Ribo Life Science has expanded its siRNA delivery platform, RiboPepSTAR™, beyond the liver to target kidneys, heart, and fat tissue, showing up to 80% gene knockdown in kidney cells across species and 96% in primate fat tissue. 临床前结果显示持续的,器官特异性静音化与最小的非目标效应. Preclinical results demonstrate sustained, organ-specific silencing with minimal off-target effects. 该公司首个向脏的候选药物正在进行IND支持开发,它正在推进一个多目标siRNA平台,该平台可以同时静止多种基因,其效率与单一准方法相比较,为脏,心脏和代谢疾病提供更广泛的治疗应用. The company’s first kidney-targeted candidate is in IND-enabling development, and it is advancing a multi-target siRNA platform that silences multiple genes simultaneously with efficacy comparable to single-target approaches, supporting broader therapeutic applications for renal, cardiac, and metabolic diseases.